京新药业(002020) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 reached ¥1,058,822,622.34, an increase of 7.06% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥172,890,109.64, reflecting a growth of 10.33% year-over-year[3]. - The net profit excluding non-recurring items was ¥159,767,636.84, up by 9.14% from the previous year[3]. - Total operating revenue for the third quarter reached CNY 3,208,743,897.71, an increase of 9.7% compared to CNY 2,925,537,429.00 in the same period last year[14]. - The net profit for Q3 2024 reached CNY 580,559,428.63, an increase of 22% compared to CNY 475,952,284.31 in Q3 2023[15]. - Operating profit for the quarter was CNY 671,815,265.63, up from CNY 535,489,200.93, reflecting a growth of approximately 25%[15]. - Basic and diluted earnings per share increased to CNY 0.67 from CNY 0.55 year-over-year[15]. Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥8,582,984,385.15, representing a 7.47% increase from the end of the previous year[3]. - Non-current assets totaled CNY 5,672,840,299.49, an increase of 22.5% from CNY 4,632,822,305.29 year-over-year[12]. - Current liabilities increased to CNY 2,362,726,673.03 from CNY 2,074,758,616.48, representing a rise of 13.9%[13]. - The company's equity attributable to shareholders rose to CNY 5,829,285,072.07, up from CNY 5,512,374,486.23, reflecting a growth of 5.7%[13]. - Short-term borrowings increased to CNY 352,000,000.00 from CNY 279,091,047.23, indicating a rise of 26.1%[12]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥612,693,212.93, showing a significant increase of 22.43% compared to the same period last year[3]. - Cash flow from operating activities generated a net amount of CNY 612,693,212.93, an increase from CNY 500,457,167.03 in the same period last year[16]. - Total cash inflow from financing activities was approximately ¥569.55 million, an increase from ¥455.94 million in the previous year[17]. - Cash outflow from financing activities totaled approximately ¥725.43 million, up from ¥617.09 million year-over-year[17]. - Net cash flow from financing activities was approximately -¥155.88 million, slightly improved from -¥161.15 million in the previous year[17]. - The net increase in cash and cash equivalents was approximately -¥1.07 billion, compared to -¥258.50 million in the same period last year[17]. - The ending balance of cash and cash equivalents was approximately ¥204.19 million, a significant decrease from ¥1.21 billion at the end of the previous year[17]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,693, with the top 10 shareholders holding 20.77% of the shares[9]. - The company has a major shareholder, Lü Gang, who holds 20.77% of the shares, amounting to 178,796,755 shares[9]. - The top 10 unrestricted shareholders collectively hold 134,966,393 shares, representing a significant portion of the company's equity[9]. - The total number of preferred shareholders is not applicable, indicating no preferred shares were issued[10]. - The company has not reported any changes in the top 10 shareholders due to securities lending activities[10]. Expenses and Income - The company's management expenses rose to ¥194,483,465.65, a 36.73% increase due to higher depreciation and employee compensation[7]. - Other income increased significantly to ¥81,503,553.50, up by 187.96% primarily due to increased government subsidies[7]. - Research and development expenses were CNY 269,444,316.12, slightly higher than CNY 259,456,442.07 from the previous year, indicating a focus on innovation[14]. - The tax expense for the quarter was CNY 95,904,869.65, up from CNY 60,140,798.91 in the previous year[15]. - The company recorded a decrease in financial expenses, with interest expenses at CNY -46,571,874.28 compared to CNY -38,235,729.66 in Q3 2023[15]. Inventory and Receivables - The company reported a substantial increase in accounts receivable, which reached ¥776,130,807.25, a rise of 35.82% attributed to higher sales[6]. - Accounts receivable increased to ¥776,130,807.25 from ¥571,455,790.11 at the beginning of the period, reflecting a significant growth in receivables[11]. - Inventory rose to ¥757,727,994.70 from ¥652,687,352.33, indicating an increase in stock levels[11]. - The trading financial assets increased to ¥865,550,308.22 from ¥150,955,942.00, showing a substantial rise in marketable securities[11]. - The company reported a notable increase in prepayments, which rose to ¥17,555,290.02 from ¥13,333,192.83[11]. Audit and Reporting - The company did not undergo an audit for the third quarter report[17]. - The company reported a net profit margin improvement, with net profit figures to be detailed in future reports, indicating positive future outlook[14].